EGFR

Epidermal growth factor receptor; ErbB-1; HER1

EGFR

EGFR Isoform Specific Products:

EGFR Isoform Comparison

EGFR Related Products (863)
Recombinant Proteins (77)
Antibodies (19)
EGFR Isoform Comparison

By Effects:	Controls (5) Inhibitors (745) Agonists (2) Degraders (17) Antagonist (1) Activators (5) Modulators (3) Chemicals (2) Inducers (4)

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-19816A

Avitinib maleate	Inhibitor	99.86%
Avitinib (Abivertinib) maleate is a third-generation, irreversible and orally active selective EGFR inhibitor, with IC₅₀ values of 0.18 nM, 0.18 nM, 7.68 nM and against EGFR L858R, EGFR T790M and wild-type EGFR. Avitinib maleate is also a BTK inhibitor that induces apoptosis and inhibits phosphorylation of BTK in mantle cell lymphoma. Avitinib maleate shows anticancer effects.

HY-137191

CH7233163	Inhibitor	99.61%
CH7233163 is a noncovalent ATP-competitive inhibitor for EGFR-Del19/T790M/C797S. CH7233163 can overcome Osimertinib (HY-15772)-Resistant EGFR-Del19/T790M/C797S mutation. CH7233163 blocks the EGFR phosphorylation in the Del19/T790M/C797S_NIH3T3 cells. CH7233163 has antitumor activities.

HY-147941A

MS9427 TFA	Degrader	99.01%
MS9427 TFA is a potent PROTAC EGFR degrader with K_ds of 7.1 nM and 4.3 nM for EGFR WT and EGFR L858R, respectively. MS9427 TFA selectively degrades the mutant but not the WT EGFR through both the ubiquitin/proteasome system (UPS) and autophagy/lysosome pathways. MS9427 TFA potently inhibits the proliferation of NSCLC cells. MS9427 TFA can be used for researching anticancer.

HY-16069A

Tucatinib hemiethanolate	Inhibitor	99.97%
Tucatinib (Irbinitinib) hemiethanolate is a potent, orally active and selective HER2 inhibitor with an IC₅₀ of 8 nM.

HY-10325

CL-387785	Inhibitor	98.05%
CL-387785(EKI785; WAY-EKI 785) is an irreversible inhibitor of EGFR with IC₅₀ of 370 pM.

HY-78869

Mutated EGFR-IN-1	Inhibitor	99.89%
Mutated EGFR-IN-1 (Osimertinib analog) is a useful intermediate for the inhibitors design for mutated EGFR, such as L858R EGFR, Exonl9 deletion activating mutant and T790M resistance mutant.

HY-141640

MS154	Inhibitor	99.42%
MS154 is a first-in-class E3 ligase cereblon-recruiting EGFR degrader with K_ds of 1.8 nM and 3.8 nM for EGFR ^WT and EGFR ^L858R mutants. MS154 potently induces the degradation of mutant but not wild-type EGFR in an E3 ligase-dependent manner in cancer cell lines. MS154 potently inhibits cell proliferation in lung cancer cells (Blue: E3 Ligase ligand (HY-103596); Black: linker (HY-W096167); Pink: EGFR ligand (HY-168305)).

HY-41404

Piperonylic acid		99.91%
Piperonylic acid is a natural molecule bearing a methylenedioxy function that closely mimics the structure of trans-cinnamic acid. Piperonylic Acid is a selective, mechanism-based inactivator of the trans-cinnamate 4-Hydroxylase. Piperonylic acid has anticancer, antioxidant and antibacterial activities.

HY-103443

HKI-357	Inhibitor	99.24%
HKI-357 is an irreversible dual inhibitor of EGFR and ERBB2 with IC₅₀s of 34 nM and 33 nM, respectively. HKI-357 suppresses EGFR autophosphorylation (at Y1068), and AKT and MAPK phosphorylation.

HY-20878

Tyrphostin AG 879	Inhibitor	99.85%
Tyrphostin AG 879 (AG 879) is a tyrosine kinase inhibitor that inhibits TrKA phosphorylation (IC₅₀ of 10 μM), but not TrKB and TrKC. Tyrphostin AG 879 is also a selective ErbB2 tyrosine kinase inhibitor with an IC₅₀ of 1 μM, and has at least 500-fold higher selectivity to ErbB2 than EGFR. Tyrphostin AG 879 has anticancer activity.

HY-124813

PDZ1i	Inhibitor	99.29%
PDZ1i is a potent, BBB-penetrated and specific MDA-9/Syntenin inhibitor. PDZ1i inhibits crucial GBM (glioblastoma multiforme) signaling involving FAK and EGFRvIII. PDZ1i reduces MMP secretion. PDZ1i can improve survival of brain tumor-bearing mice and reduce tumor invasion.

HY-N2510

Myristicin	Inhibitor	99.89%
Myristicine is an orally bioavailable serotonin receptor antagonist and weak monoamine oxidase (MAO) inhibitor. Myristicine also exerts anti-cancer effects on gastric cancer cells by inhibiting the EGFR/ERK signaling pathway. Myristicine is the main component of nutmeg essential oil and has anti-cancer, anti-proliferative, antibacterial, anti-inflammatory and apoptosis-inducing effects. Myristicine abuse can produce hallucinogenic effects, organ damage, etc.

HY-155537

Pruvonertinib	Inhibitor	99.50%
YK-029A is an orally active inhibitor of mutant EGFR，targeting to both the T790M mutations (EGFR^T790M) and exon 20 insertion of EGFR (EGFRex20ins). YK-029A exhibits significant antitumor activity，and results tumor regression in EGFRex20ins-driven PDX models.

HY-123578

NSC689857	Inhibitor	99.65%
NSC689857 is a potent EGFR and SCF^SKP2 inhibitor with an IC₅₀ value of 36 μM for Skp2-Cks1. NSC689857 can inhibit p27 ubiquitylation (IC₅₀=30 μM). NSC689857 has varied activity across cancer types, with more activity against leukemia cell lines than others.

HY-10261B

(E/Z)-Afatinib	Inhibitor	99.98%
(E/Z)-Afatinib ((E/Z)-BIBW 2992) is the mixture of (E)-Afatinib and (Z)-Afatinib. Afatinib (HY-10261) is an irreversible inhibitor of EGFR, by irreversibly binding to their ATP binding site to block activation of EGFR, HER2, HER4, and EGFRvIII. Afatinib used in co-administration with Temozolomide (HY-17364), potently targeting to EGFRvIII-cMet signaling in glioblastoma cells.

HY-101219

VEGFR-IN-1	Inhibitor	98.42%
VEGFR-IN-1 (compound 3) is a potent angiogenesis inhibitor with IC₅₀s of 0.02, 0.18, 0.24 7.3, and 7 µM for VEGFR2/KDR/Flk-1, Flt-1, c-Kit, EGF-R, and c-Src, respectively.

HY-13895

WHI-P154	Inhibitor	99.39%
WHI-P154 is a potent EGFR inhibitor, and also modestly blocks JAK3, with IC₅₀s of 4 nM and 1.8 μM, respectively.

HY-19729

Naquotinib	Inhibitor	98.71%
Naquotinib (ASP8273) is an orally available, mutant-selective and irreversible EGFR inhibitor; with IC₅₀s of 8-33 nM toward EGFR mutants and 230 nM for EGFR.

HY-134877

BAY 2476568	Inhibitor	99.88%
BAY 2476568 is a potent and selective EGFR inhibitor, with IC₅₀s of < 0.2 nM for wild-type EGFR and several mutations (EGFRR ex20insSVD, EGFRR ex20insASV, EGFRR ex20insNPG).

HY-19815

Olafertinib	Inhibitor	99.51%
Olafertinib is a third-generation EGFR TKI, with GI₅₀ values of 5 nM (EGFR L858R/T790M), 10 nM (EGFR del19) and 689 nM (EGFR WT), respectively. Olafertinib has the potential for NSCLC research.

EGFR Isoform Comparison

EGFR/ErbB1/HER1

ErbB2/HER2

ErbB3/HER3

ErbB4/HER4

EGFR Degraders, Inducers, Inhibitors, Agonists, Antagonists, Activators & Modulators

Product Name	EGFR/ErbB1/HER1	ErbB2/HER2	ErbB3/HER3	ErbB4/HER4	Purity

Osimertinib	EGFR^L858R, IC₅₀: 12 nM (Enzyme assays) EGFR^L858R/T790M, IC₅₀: 1 nM (Enzyme assays)				99.96%
Trastuzumab		HER2			99.80%
Cetuximab	Soluble EGFR, Kd: 0.201 nM EGFR, Kd: 0.147 nM (Fixed A431 cells)				99.70%
Gefitinib	EGFR				99.95%
Erlotinib	EGFR, IC₅₀: 2 nM (Cell Free Assay)				99.99%
Afatinib	EGFR, IC₅₀: 0.5 nM EGFR^L858R, IC₅₀: 0.4 nM EGFR^L858R/T790M, IC₅₀: 10 nM	HER2, IC₅₀: 14 nM			99.92%
Lapatinib	EGFR, IC₅₀: 10.2 nM (Cell Free Assay)	ErbB2, IC₅₀: 9.8 nM (Cell Free Assay)			99.83%
Genistein	EGFR, IC₅₀: 0.6 μM (Cell Assay)				99.82%
AG490	EGFR				99.86%
Tucatinib		HER2			99.82%
Neratinib	EGFR, IC₅₀: 92 nM	HER2, IC₅₀: 59 nM			99.94%
Disitamab vedotin		HER2			≥99.0%
Pertuzumab		HER2			99.80%
Dacomitinib	EGFR, IC₅₀: 6 nM	ErbB2, IC₅₀: 45.7 nM		ErbB4, IC₅₀: 73.7 nM	99.74%
AG-1478	EGFR, IC₅₀: 3 nM				99.57%
Osimertinib mesylate	EGFR^L858R/T790M, IC₅₀: 1 nM EGFR^L858R, IC₅₀: 12 nM				99.97%
NSC 228155	EGFR				≥98.0%
Lazertinib	EGFR^T790M				99.87%
Erlotinib Hydrochloride	EGFR, IC₅₀: 2 nM				99.94%
Zanidatamab		HER2
Sapitinib	EGFR, IC₅₀: 4 nM	ErbB2, IC₅₀: 3 nM	HER3, IC₅₀: 4 nM		99.93%
Mobocertinib	EGFR (WT) EGFR exon 20 insertion	HER2			99.60%
Almonertinib	EGFR^T790M, IC₅₀: 0.37 nM EGFR^L858R/T790M, IC₅₀: 0.29 nM EGFR^{del19 T790M}, IC₅₀: 0.21 nM				99.83%
CUDC-101	EGFR, IC₅₀: 2.4 nM	HER2, IC₅₀: 15.7 nM			99.05%
Pyrotinib	EGFR, IC₅₀: 13 nM	HER2, IC₅₀: 38 nM			99.89%
Firmonertinib mesylate	EGFR				99.97%
Afatinib dimaleate	EGFR, IC₅₀: 0.5 nM EGFR^L858R, IC₅₀: 0.4 nM EGFR^L858R/T790M, IC₅₀: 10 nM	HER2, IC₅₀: 14 nM			99.74%
Icotinib	EGFR, IC₅₀: 5 nM				99.99%
Gefitinib hydrochloride	EGFR				99.85%
Pelitinib	EGFR, IC₅₀: 38.5 nM				99.13%
Chrysophanol	EGFR				99.77%
Lifirafenib	EGFR, IC₅₀: 29 nM EGFR^L858R/T790M, IC₅₀: 495 nM				98.73%
Butein	EGFR, IC₅₀: 16 μM (in HepG2 cells)				99.95%
Daphnetin	EGFR, IC₅₀: 7.67 μM				99.86%
Mubritinib		HER2, IC₅₀: 6 nM			99.91%
Canertinib	EGFR, IC₅₀: 7.4 nM	ErbB2, IC₅₀: 9 nM			99.74%
TX1-85-1			ErbB3, IC₅₀: 23 nM		98.28%
Olmutinib	EGFR^{Exon 19 deletion}, IC₅₀: 9.2 nM (Cell Assay) EGFR^L858R/T790M, IC₅₀: 10 nM (Cell Assay)				99.88%
Osimertinib dimesylate	EGFR^L858R, IC₅₀: 12 nM EGFR^L858R/T790M, IC₅₀: 1 nM				99.96%
Sunvozertinib	EGFR exon 20 insertion, IC₅₀: 20.4 nM EGFR^L858R/T790M, IC₅₀: 1.1 nM	Her2 Exon20 YVMA, IC₅₀: 7.5 nM			99.71%
Lapatinib ditosylate	EGFR, IC₅₀: 10.8 nM (Cell Free Assay)	ErbB2, IC₅₀: 9.2 nM (Cell Free Assay)			99.98%
PD153035	EGFR, Ki: 6 pM EGFR, IC₅₀: 25 pM				98.83%
Zorifertinib	EGFR, IC₅₀: 0.3 nM EGFR^L858R, IC₅₀: 0.2 nM EGFR^{Exon 19 deletion}, IC₅₀: 0.2 nM				99.37%
Petosemtamab	EGFR, Kd: 0.22 nM
Disitamab		HER2			98.70%
AZ-5104	EGFR^L858R/T790M, IC₅₀: 1 nM EGFR^L858R, IC₅₀: 1 nM EGFR^L861Q, IC₅₀: 6 nM EGFR, IC₅₀: 25 nM			ErbB4, IC₅₀: 7 nM	99.69%
Gefitinib-based PROTAC 3	EGFR, DC₅₀: 11.7 nM (HCC827(exon 19 del) cells) EGFR, DC₅₀: 22.3 nM (H3255 (L858R mutantion) cells)				99.98%
Avitinib	EGFR L858R, IC₅₀: 0.18 nM EGFR^T790M, IC₅₀: 0.18 nM EGFR (WT), IC₅₀: 7.68 nM				99.95%
Rociletinib	EGFR^L858R/T790M, Ki: 21.5 nM EGFR^T790M, Ki: 303.3 nM				99.79%
Pertuzumab (anti-HER2)		HER2			99.10%
CP-724714		ErbB2, IC₅₀: 10 nM			98.37%
Pyrotinib dimaleate	EGFR, IC₅₀: 13 nM	HER2, IC₅₀: 38 nM			98.56%
EAI045	EGFR, IC₅₀: 1.9 μM EGFR^L858R, IC₅₀: 0.019 μM EGFR^T790M, IC₅₀: 0.19 μM EGFR^L858R/T790M, IC₅₀: 0.002 μM				99.08%
Tesevatinib	EGFR, IC₅₀: 0.3 nM	ErbB2, IC₅₀: 16 nM			99.41%
Tyrphostin 23	EGFR, IC₅₀: 35 μM (Cell Assay) EGFR, Ki: 11 μM				98.19%
PD168393	EGFR, IC₅₀: 0.7 nM				98.58%
Varlitinib	HER1, IC₅₀: 7 nM	HER2, IC₅₀: 2 nM		HER4, IC₅₀: 4 nM	98.03%
Lapatinib ditosylate monohydrate	EGFR, IC₅₀: 10.8 nM	ErbB2, IC₅₀: 9.2 nM			99.93%
Firmonertinib	EGFR				99.89%
AEE788	EGFR, IC₅₀: 2 nM	ErbB2, IC₅₀: 6 nM			99.13%
WZ4002	EGFR^L858R, IC₅₀: 2 nM (Cell Assay) EGFR^L858R/T790M, IC₅₀: 8 nM (Cell Assay) EGFR^E746_A750, IC₅₀: 3 nM (Cell Assay) EGFR^{E746_A750/T790M}, IC₅₀: 2 nM (Cell Assay)				98.99%
Icotinib Hydrochloride	EGFR, IC₅₀: 5 nM				99.81%
PD158780	EGFR, IC₅₀: 8 μM (Cell Assay)	ErbB2, IC₅₀: 49 nM (Cell Assay)	ErbB3, IC₅₀: 52 nM (Cell Assay)	ErbB4, IC₅₀: 52 nM (Cell Assay)	99.56%
Nazartinib	EGFR^L858R/T790M, Ki: 31 nM				99.03%
Zipalertinib	EGFR, IC₅₀: 1.1-8.0 nM				99.81%
BMS-690514	EGFR, IC₅₀: 5 nM	HER2, IC₅₀: 20 nM		HER4, IC₅₀: 60 nM	99.07%
Rezivertinib	EGFR				99.43%
Neratinib maleate	EGFR, IC₅₀: 92 nM	HER2, IC₅₀: 59 nM			99.83%
Genistein (Standard)	EGFR				99.31%
Lumretuzumab			HER3		≥99.0%
JBJ-09-063 hydrochloride	EGFR L858R, IC₅₀: 0.147 nM EGFR L858R/T790M, IC₅₀: 0.063 nM EGFR L858R/T790M/C797S, IC₅₀: 0.083 nM EGFRLT/L747S, IC₅₀: 0.396 nM				99.37%
AG-825	EGFR, IC₅₀: 19 μM	ErbB2, IC₅₀: 0.35 μM			98.02%
BI-4020	EGFR^{del19 T790M C797S}, IC₅₀: 0.2 nM EGFR^del19, IC₅₀: 1 nM EGFR^WT, IC₅₀: 190 nM				99.28%
Mobocertinib succinate	EGFR exon 20 insertion EGFR (WT)	HER2			99.83%
TAK-285	EGFR, IC₅₀: 23 nM	HER2, IC₅₀: 17 nM			99.70%
Falnidamol	EGFR, IC₅₀: 3 nM	ErbB2, IC₅₀: 3.4 μM			99.41%
Tuxobertinib	EGFR, Kd: 0.2 nM	HER2, Kd: 0.76 nM			99.90%
Allitinib tosylate	EGFR, IC₅₀: 0.5 nM EGFR^L858R/T790M, IC₅₀: 12 nM	ErbB2, IC₅₀: 3 nM		ErbB4, IC₅₀: 0.8 nM	99.83%
limertinib	EGFR^T790M, IC₅₀: 0.5 nM EGFR^L858R/T790M, IC₅₀: 0.3 nM EGFR (WT), IC₅₀: 6 nM EGFR^{Exon 19 deletion}, IC₅₀: 0.5 nM				99.12%
Bafisontamab	EGFR
WZ-3146	EGFR^L858R, IC₅₀: 2 nM EGFR^L858R/T790M, IC₅₀: 5 nM EGFR^E746_A750, IC₅₀: 2 nM EGFR^{E746_A750/T790M}, IC₅₀: 14 nM EGFR, IC₅₀: 24 nM				99.63%
Canertinib dihydrochloride	EGFR, IC₅₀: 7.4 nM	ErbB2, IC₅₀: 9 nM			99.68%
Almonertinib hydrochloride	EGFR^T790M, IC₅₀: 0.37 nM EGFR^L858R/T790M, IC₅₀: 0.29 mM EGFR^{del19 T790M}, IC₅₀: 0.214 nM				99.77%
PD-161570	EGFR, IC₅₀: 240 nM				99.82%
Avitinib maleate	EGFR (WT), IC₅₀: 7.68 nM EGFR L858R, IC₅₀: 0.18 nM EGFR^T790M, IC₅₀: 0.18 nM				99.86%
CL-387785	EGFR, IC₅₀: 370 pM				98.05%
Mutated EGFR-IN-1	EGFR^L858R EGFR^{Exon 19 deletion/T790M} EGFR^T790M				99.89%
MS154	EGFR (WT), Kd: 1.8 nM EGFR^L858R, Kd: 3.8 nM				99.42%
Piperonylic acid	EGFR				99.91%
HKI-357	EGFR, IC₅₀: 34 nM	ErbB2, IC₅₀: 33 nM			99.24%
Myristicin	EGFR				99.89%
VEGFR-IN-1	EGFR, IC₅₀: 0.24 μM				98.42%
WHI-P154	EGFR, IC₅₀: 4 nM				99.39%
Naquotinib	EGFR, IC₅₀: 230 nM				98.71%
Naquotinib mesylate	EGFR^L858R/T790M EGFR^L858R EGFR^{Exon 19 deletion} EGFR^{Exon 19 deletion/T790M} EGFR, IC₅₀: 230 nM				98.05%
Epertinib hydrochloride	EGFR, IC₅₀: 1.48 ± 0.0 nM	HER2, IC₅₀: 7.15 nM		HER4, IC₅₀: 2.49 ± 0.1 nM	98.15%
MTX-211	EGFR				99.81%
EGFR-IN-11	EGFR^{L858R/T790M/C797S}, IC₅₀: 18 nM				99.30%
Anbenitamab		Human HER2			99.22%
EGFR/ErbB-2/ErbB-4 inhibitor-3	ErbB1, IC₅₀: 0.3 nM EGFR, IC₅₀: 2.5 nM	ErbB2, IC₅₀: 1.1 nM		ErbB4, IC₅₀: 0.5 nM	98.19%
CGP52411	EGFR, IC₅₀: 0.3 μM				99.82%
Allitinib	EGFR, IC₅₀: 0.5 nM EGFR^L858R/T790M, IC₅₀: 12 nM	ErbB2, IC₅₀: 3 nM		ErbB4, IC₅₀: 0.8 nM	99.36%
Oritinib	EGFR (WT), IC₅₀: 18 nM EGFR^L858R, IC₅₀: 0.7 nM EGFR^L861Q, IC₅₀: 4 nM EGFR^L858R/T790M, IC₅₀: 0.1 nM EGFR^d746-750, IC₅₀: 1.4 nM EGFR^{d746-750/T790M}, IC₅₀: 0.89 nM				99.59%
Tarlox-TKI	EGFR				98.84%
Selatinib	EGFR, IC₅₀: 13 nM	ErbB2, IC₅₀: 22.5 nM			99.83%
EGFR kinase inhibitor 3	EGFR (WT), IC₅₀: <10 nM EGFR L858R, IC₅₀: 1.5 nM EGFR L858R/T790M, IC₅₀: 0.059 nM EGFR L858R/T790M/C797S, IC₅₀: 0.064 nM				99.03%
Simotinib	EGFR, IC₅₀: 19.9 nM				99.39%
PF-6274484	EGFR (WT), Ki: 0.18 nM EGFR^L858R/T790M, Ki: 0.14 nM				98.76%
BI-1622		HER2, IC₅₀: 7 nM			98.97%
PD153035 Hydrochloride	EGFR, Ki: 6 pM EGFR, IC₅₀: 25 pM				99.48%
EGFR-IN-12	EGFR (WT), IC₅₀: 21 nM EGFR^L858R, IC₅₀: 63 nM EGFR^L861Q, IC₅₀: 4 nM			HER4, IC₅₀: 7640 nM	99.40%
HG-14-10-04	EGFR^LR/TM, IC₅₀: 15.6 nM EGFR^19del/TM/CS, IC₅₀: 22.6 nM EGFR^LR/TM/CS, IC₅₀: 124.5 nM				99.09%
Tarloxotinib bromide		EGFR/HER2			99.26%
GW2974	EGFR^L858R/T790M, IC₅₀: 0.007 μM	HER2, IC₅₀: 0.016 μM			99.54%
TAS0728	EGFR, IC₅₀: 65 nM	HER2, IC₅₀: 13 nM		HER4, IC₅₀: 8.5 nM	99.71%
MS9449	EGFR (WT), Kd: 17 nM EGFR L858R, Kd: 10 nM				98.95%
Larotinib mesylate hydrate	EGFR (WT), IC₅₀: 0.611 nM EGFR^L858R, IC₅₀: 0.563 nM EGFR^L861Q, IC₅₀: 0.423 nM EGFR^T790M, IC₅₀: 45.2 nM	HER2, IC₅₀: 253 nM		HER4, IC₅₀: 84 nM	98.66%
JBJ-09-063 TFA	EGFR L858R, IC₅₀: 0.147 nM EGFR L858R/T790M, IC₅₀: 0.063 nM EGFR L858R/T790M/C797S, IC₅₀: 0.083 nM EGFRLT/L747S, IC₅₀: 0.396 nM				99.64%
BI-4142		HER2, IC₅₀: 5 nM			98.39%
Trastuzumab rezetecan		HER2			98.61%
EGFR/ErbB-2/ErbB-4 inhibitor-2	EGFR, IC₅₀: 0.017 μM	ErbB2, IC₅₀: 0.08 μM		ErbB4, IC₅₀: 1.91 μM	99.45%
AG 555	EGFR				≥98.0%
PD-089828	EGFR, IC₅₀: 5.47 μM EGFR, Ki: 3.16 μM				98.07%
PROTAC EGFR degrader 2	EGFR, DC₅₀: 36.51 nM
AV-412 free base	EGFR, IC₅₀: 0.75 nM EGFR^L858R, IC₅₀: 0.51 nM EGFR^L858R/T790M, IC₅₀: 2.3 nM EGFR^T790M, IC₅₀: 0.79 nM	ErbB2, IC₅₀: 19 nM			98.33%
Theliatinib	EGFR, IC₅₀: 3 nM EGFR, Ki: 0.05 nM EGFR (L858R/T790M), IC₅₀: 22 nM				99.77%
WHI-P180	EGFR, IC₅₀: 4 μM				99.84%
EGFR-IN-5	EGFR, IC₅₀: 10.4 nM EGFR^L858R, IC₅₀: 1.1 nM EGFR^L858R/T790M, IC₅₀: 34 nM EGFR^{L858R/T790M/C797S}, IC₅₀: 7.2 nM				99.49%
Mutant EGFR inhibitor	EGFR^L858R EGFR^{Exon 19 deletion} EGFR^T790M				99.51%
NRC-2694	EGFR				99.45%
CNX-2006	EGFR^T790M, IC₅₀: 20 nM				98.42%
(Rac)-JBJ-04-125-02	EGFR (L858R/T790M), IC₅₀: 0.26 nM
EGFR-IN-7	EGFR (WT), IC₅₀: 7.92 nM EGFR (C797S/T790M/L858R), IC₅₀: 0.218 nM				99.76%
EGFR-IN-17	EGFR (C797S/T790M/L858R), IC₅₀: 0.0002 μM				98.18%
Cinrebafusp alfa		HER2, Kd: 0.3 nM			98.53%
PROTAC EGFR degrader 9	EGFR^{L858R/T790M/C797S}, DC₅₀: 10.2 nM EGFR^{L858R/T790M/C797S}, Kd: 240.2 nM EGFR^{del19 T790M C797S}, DC₅₀: 36.5 nM EGFR^L858R/T790M, DC₅₀: 88.5 nM EGFR^del19, DC₅₀: 75.4 nM EGFR (WT), DC₅₀: >300 nM				98.35%
Lavendustin C	EGFR, IC₅₀: 0.012 μM				98.32%
Astragaloside VI	EGFR				99.95%
Tyrphostin AG 528	EGFR, IC₅₀: 4.9 μM	ErbB2, IC₅₀: 2.1 μM			≥98.0%
EGFR-IN-89	EGFR^19del/TM/CS, IC₅₀: 10.1 nM				98.75%
AG-494	EGFR, IC₅₀: 0.7 μM				99.31%
RG14620	EGFR, IC₅₀: 3 μM (Cell Assay)				98.09%
JNJ28871063 hydrochloride	ErbB1, IC₅₀: 22 nM	ErbB2, IC₅₀: 38 nM		ErbB4, IC₅₀: 21 nM	98.36%
EMI1	EGFR^{del19 T790M C797S} EGFR^{L858R/T790M/C797S}				99.78%
HX103	EGFR^del19, IC₅₀: 1.3 nM EGFR^L858R, IC₅₀: 1.5 nM EGFR^T790M, IC₅₀: 977 nM EGFR^WT, IC₅₀: 4.0 nM				99.10%
AV-412	EGFR, IC₅₀: 0.75 nM EGFR^L858R, IC₅₀: 0.5 nM EGFR^T790M, IC₅₀: 0.79 nM EGFR^L858R/T790M, IC₅₀: 2.3 nM	ErbB2, IC₅₀: 19 nM			99.17%
ZD-4190	EGFR				98.08%
PROTAC EGFR degrader 7	EGFR^L858R/T790M, DC₅₀: 13.2 nM				99.99%
Perzebertinib		HER2
Epertinib	EGFR, IC₅₀: 1.48 ± 0.0 nM	HER2, IC₅₀: 7.15 ± 0.5 nM		HER4, IC₅₀: 2.49 ± 0.1 nM	≥98.0%
MC-Val-Cit-PAB-Amide-TLR7 agonist 4		HER2			99.39%
(E)-AG 99	EGFR				98.36%
EGFR-IN-1 hydrochloride	EGFR^L858R/T790M
EGFR-IN-1	EGFR^L858R/T790M
MS9427	EGFR (WT), Kd: 7.1 nM EGFR L858R, Kd: 4.3 nM
JBJ-09-063	EGFR L858R, IC₅₀: 0.147 nM EGFR L858R/T790M, IC₅₀: 0.063 nM EGFR L858R/T790M/C797S, IC₅₀: 0.083 nM EGFRLT/L747S, IC₅₀: 0.396 nM
Mutated EGFR-IN-3	EGFR^L858R/T790M, IC₅₀: 12 nM EGFR^C797S, IC₅₀: 13 nM
Gozanertinib	EGFR^L858R/T790M, IC₅₀: 48 nM EGFR^WT, IC₅₀: 15 nM				98.37%
(S)-Sunvozertinib	EGFR exon 20 NPH, IC₅₀: 51.2 nM EGFR exon 20 ASV insertion, IC₅₀: 51.9 nM EGFR^L858R/T790M, IC₅₀: 1 nM	Her2 exon 20 YVMA insertion, IC₅₀: 21.2 nM			99.14%
Larotinib	EGFR (WT), IC₅₀: 0.611 nM EGFR^L858R, IC₅₀: 0.563 nM EGFR^L861Q, IC₅₀: 0.423 nM EGFR^T790M, IC₅₀: 45.2 nM	HER2, IC₅₀: 253 nM		HER4, IC₅₀: 84 nM	99.50%
SU5204		HER2, IC₅₀: 51.5 μM			99.46%
Laprituximab emtansine	HER1
Rociletinib hydrobromide	EGFR^L858R/T790M, Ki: 21.5 nM EGFR^T790M, Ki: 303.3 nM				98.04%
MJ04	EGFR, IC₅₀: 3267 nM				98.08%
JBJ-04-125-02	EGFR (L858R/T790M), IC₅₀: 0.26 nM
pan-HER-IN-2	EGFR, IC₅₀: 0.72 nM EGFR (L858R/T790M), IC₅₀: 8.2 nM	HER2, IC₅₀: 75.1 nM		HER4, IC₅₀: 2.0 nM	98.10%
EGFR/HER2-IN-9	EGFR, IC₅₀: 3.2 nM EGFR^T790M, IC₅₀: 8.3 nM	HER2, IC₅₀: 14 nM			98.73%
YS-363	EGFR, IC₅₀: 0.96 nM				99.52%
EGFR-IN-1 TFA	EGFR^L858R/T790M				99.38%
PKC-IN-6	EGFR, IC₅₀: >100 μM				99.63%
Inetetamab		HER2
EGFR-IN-69	EGFR L858R/T790M/C797S, IC₅₀: 4.3 ± 0.9 nM EGFR^L858R/T790M, IC₅₀: 6.6 ± 0.8 nM EGFR^{del19 T790M C797S}, IC₅₀: 25.6 ± 7.5 nM EGFR^WT, IC₅₀: 816.0 ± 82 nM				99.58%
CHMFL-EGFR-202	EGFR^T790M, IC₅₀: 5.3 nM EGFR, IC₅₀: 8.3 nM	ErbB2, IC₅₀: 8.1 nM		ErbB4, IC₅₀: 3.2 nM	99.75%
T-1-PMPA	EGFR^WT, IC₅₀: 86 nM EGFR^T790M, IC₅₀: 561.73 nM				99.70%
ZM 449829	EGFR, pIC₅₀: 5.0				99.73%
SHR-A1201		HER2
Nazartinib mesylate	EGFR^L858R/T790M, Ki: 31 nM
BGB-102	EGFR, IC₅₀: 9.6 nM	HER2, IC₅₀: 18 nM		HER4, IC₅₀: 40.3 nM	99.52%
Afatinib oxalate	EGFR^L858R, IC₅₀: 0.4 nM EGFR^WT, IC₅₀: 0.5 nM EGFR^L858R/T790M, IC₅₀: 10 nM	HER2, IC₅₀: 14 nM
JBJ-02-112-05	EGFR^L858R/T790M, IC₅₀: 15 nM
Mobocertinib mesylate	EGFR exon 20 insertion EGFR (WT)	HER2
Lapatinib tosylate	EGFR, IC₅₀: 10.2 nM	ErbB2, IC₅₀: 9.8 nM
EGFR/CSC-IN-1	EGFR, IC₅₀: 10.52 nM
TX2-121-1			HER3, IC₅₀: 49 nM
Mutated EGFR-IN-2	EGFR (L858R/T790M), IC₅₀: <1 nM
Oritinib mesylate	EGFR (WT), IC₅₀: 18 nM EGFR^L858R, IC₅₀: 0.7 nM EGFR^L861Q, IC₅₀: 4 nM EGFR^L858R/T790M, IC₅₀: 0.1 nM EGFR^d746-750, IC₅₀: 1.4 nM EGFR^{d746-750/T790M}, IC₅₀: 0.89 nM
EMI56	EGFR^{L858R/T790M/C797S} EGFR^{del19 T790M C797S}				99.72%
EMI48	EGFR^{L858R/T790M/C797S} EGFR^{del19 T790M C797S}				99.02%
EGFR-IN-15	EGFR, IC₅₀: 4 nM
EGFR/HER2-IN-2	EGFR, IC₅₀: 5.02 μM	HER2, IC₅₀: 0.83 μM
Sacibertinib	EGFR-TK phosphorylation, EC₅₀: 110 nM	HER2, EC₅₀: 244 nM
Gancotamab		HER2
SU 5402 (GMP)	EGFR, IC₅₀: 30 nM
HER2-IN-5		HER2
EGFR-IN-36	EGFR (WT), IC₅₀: 19.09 nM	HER2(WT), IC₅₀: 120.01 nM HER2 (A775_G776insYVMA), IC₅₀: 2.35 nM
EGFR/BRAF-IN-1	EGFR
Gamendazole		ErbB2
pan-HER-IN-1	EGFR, IC₅₀: 0.38 nM EGFR^{L858R/T790M/C797S}, IC₅₀: 2.2 nM	HER2, IC₅₀: 3.5 nM		HER4, IC₅₀: 1.6 nM
BMS-599626 dihydrochloride	HER1, IC₅₀: 20 nM	HER2, IC₅₀: 30 nM
EGFR-IN-74	EGFR^L858R/T790M, IC₅₀: 138 nM
EGFR/HER2-IN-5	EGFR, IC₅₀: 0.6 nM	HER2, IC₅₀: 0.6 nM
JBJ-07-149	EGFR^L858R/T790M, IC₅₀: 1.1 nM
HER2-IN-12		HER2, IC₅₀: 121 nM
EGFR-IN-92	EGFR L858R/T790M
Multi-kinase-IN-4		HER2, IC₅₀: 0.18 mM
GLUT1/EGFR-IN-1	EGFR				99.75%
Chrysophanol (Standard)	EGFR
EGFR/C797S-IN-1	EGFR^{L858R/T790M/C797S}, IC₅₀: 0.128 μM
PROTAC EGFR degrader 5	EGFR, DC₅₀: 34.8 nM
Dual Galectin-3/EGFR-IN-1	EGFR, Kd: 3.31 μM
HER2-IN-8		HER2
EGFR-IN-46	EGFR, IC₅₀: 20.17 nM
(E/Z)-CP-724714		HER2
PDE5-IN-3	EGFR, IC₅₀: 5.827 μM
EGFR WT/T790M-IN-2	EGFR^T790M, IC₅₀: 0.08 μM EGFR^WT, IC₅₀: 0.13 μM
EGFR/HER2-IN-10	EGFR, IC₅₀: 2.3 nM	HER2, IC₅₀: 234 nM
EGFR-IN-60	EGFR, IC₅₀: 0.083 μM EGFR^L858R, IC₅₀: 0.053 μM EGFR^T790M, IC₅₀: 0.026 μM
Cyclic(YCDGFYACYMDV)		HER2
JGK-068S	EGFR
EGFR T790M/L858R-IN-4	EGFR^L858R/T790M
EGFR-IN-62	EGFR^L858R/T790M, IC₅₀: 10 ± 1 EGFR (WT), IC₅₀: 29 ± 2 EGFR^{L858R/T790M/C797S}, IC₅₀: 242 ± 9
EGFR-IN-52	EGFR, IC₅₀: 0.358 μM EGFR^L858R, IC₅₀: 86.02 μM EGFR^T790M, IC₅₀: 432.67 μM
AZ14240475	EGFR exon 20 insertion
EGFR-IN-3	EGFR^WT, IC₅₀: 0.32 μM
EGFR-IN-80	EGFR, pIC₅₀: 10.6
EGFR-IN-49	EGFR^T790M, IC₅₀: 65.0 nM EGFR^L858R/T790M, IC₅₀: 13.6 nM
EGFR-IN-73	EGFR^del19, IC₅₀: 119 nM EGFR^L858R, IC₅₀: 820 nM EGFR^WT, IC₅₀: >10 μM EGFR^L858R/T790M, IC₅₀: >10 μM
EGFR-IN-106	EGFR, IC₅₀: 0.2396 μM
EGFR ligand-2	EGFR^L858R, IC₅₀: 21 nM EGFR^L858R/T790M, IC₅₀: 48 nM
EGFR-IN-124	EGFR, IC₅₀: 0.54 μM
EGFR T790M/L858R-IN-2	EGFR^L858R/T790M, IC₅₀: 3.5 nM EGFR (WT), IC₅₀: 1290 nM EGFR^T790M, IC₅₀: 6.7 nM EGFR^L858R, IC₅₀: 2.1 nM				99.66%
TAS-121	EGFR L858R, IC₅₀: 1.7 nM EGFR (ex19del), IC₅₀: 2.7 nM EGFR L858R/T790M, IC₅₀: 0.56 nM EGFR (ex19del/T790M), IC₅₀: 1.1 nM EGFR (WT), IC₅₀: 8.2 nM	HER2, IC₅₀: 110 nM		HER4, IC₅₀: 2.6 nM
EGFR-IN-21	EGFR, IC₅₀: 0.38 nM
EGFR-IN-28	EGFR
EGFR/COX-2-IN-1	EGFR^T790M, IC₅₀: 0.076 μM EGFR (WT), IC₅₀: 0.12 μM
EGFR/HER2/TS-IN-2	EGFR, IC₅₀: 0.173 ± 0. μM	HER2, IC₅₀: 0.125 ± 0. μM
EGFR/HER2-IN-4	EGFR, IC₅₀: 0.6 nM
EGFR-IN-55	EGFR^L858R/T790M, IC₅₀: 3.9 nM EGFR^WT, IC₅₀: 70 nM
EGFR-IN-116	EGFR, IC₅₀: 0.103 μM
EGFR/HER2-IN-3	EGFR	HER2
EGFR-IN-29	EGFR^T790M
EGFR-IN-133	EGFR (WT), IC₅₀: 0.1 nM
EGFR-IN-137	EGFR, IC₅₀: 0.192 μM
Emupertinib	EGFR (L858R/T790M/C797S), IC₅₀: 0.52 nM EGFR (d746-750/T790M/C779S), IC₅₀: <0.3 nM EGFR (d746-750/C797S), IC₅₀: 0.5 nM EGFR (WT), IC₅₀: 0.92 nM
EGFR-IN-22	EGFR^{L858R/T790M/C797S}, IC₅₀: 0.54 nM EGFR (WT), IC₅₀: 4.91 nM
EGFR-IN-75	EGFR^WT, IC₅₀: 0.28 μM EGFR^T790M, IC₅₀: 5.02 μM
RET-IN-19	EGFR, IC₅₀: 56.78 ± 4. μM
DPPY	EGFR, IC₅₀: <10 nM
HER2-IN-18	EGFR (WT), IC₅₀: 500-1500 n nM	HER2(WT), IC₅₀: <200 nM HER2 YVMA, IC₅₀: <200 nM
HSP90-IN-13	EGFR, IC₅₀: 38.5 nM
HER2-IN-9		HER2, IC₅₀: 0.03 μM
EP26	EGFR, IC₅₀: 48.6 nM
EGFR kinase inhibitor 1	EGFR (WT), IC₅₀: 37 nM EGFR^L858R/T790M, IC₅₀: 1.7 nM EGFR^{L858R/T790M/C797S}, IC₅₀: >300 nM
EGFR-IN-56	EGFR^T790M, IC₅₀: 541.7 nM EGFR^L858R/T790M, IC₅₀: 132.1 nM
HER2-IN-20	EGFR (WT), IC₅₀: 4584 nM	HER2(WT), IC₅₀: 49 nM HER2 YVMA, IC₅₀: 42 nM
EGFR-IN-27	EGFR^del19, IC₅₀: <50 nM EGFR^L858R, IC₅₀: <50 nM EGFR^L858R/T790M, IC₅₀: <50 nM EGFR^{del19 T790M C797S}, IC₅₀: <50 nM EGFR (C797S/T790M/L858R), IC₅₀: <50 nM EGFR^{del19 T790M}, IC₅₀: <50 nM
EGFR-IN-115	EGFR, IC₅₀: 395.2 nM
EGFR/VEGFR2-IN-5	EGFR^T790M, IC₅₀: 0.28 μM
HER2-IN-17		Her2 exon 20 YVMA insertion, IC₅₀: <200 nM
EGFR/HER2-IN-15	EGFR (WT), IC₅₀: 37.21 nM
EGFR-IN-30	EGFR (WT), IC₅₀: 1-10 nM EGFR (L858R/T790M/C797S), IC₅₀: <1 nM
HER2-IN-13	EGFR (WT), IC₅₀: 0.40 μM	HER2, IC₅₀: 8 nM
EGFR-IN-127	EGFR^ex19del, IC₅₀: 136.3 nM EGFR^19del/TM/CS, IC₅₀: 161.2 nM
Simotinib hydrochloride	EGFR, pIC₅₀: 19.9 nM
PD 173955 analog 1	EGFR, IC₅₀: 0.19 μM
EGFR/HER2/DHFR-IN-3	EGFR, IC₅₀: 0.138 μM	HER2, IC₅₀: 0.092 μM
EGFR-IN-57	EGFR, IC₅₀: 0.054 μM
EGFR-IN-16	EGFR, pIC₅₀: 4.85	HER2, pIC₅₀: 4.74
EGFR-IN-109	EGFR, IC₅₀: 25.8 nM EGFR^T790M, IC₅₀: 182.3 nM
HER2-IN-15		Her2 exon 20 YVMA insertion, IC₅₀: <200 nM
EGFR-IN-67	EGFR, IC₅₀: 0.34 μM
EGFR/VEGFR2-IN-3	EGFR, IC₅₀: 0.129 μM
EGFR-IN-134	EGFR, IC₅₀: 0.023 μM
HER2-IN-16		Her2 exon 20 YVMA insertion, IC₅₀: <200 nM
EGFR-IN-64	EGFR, IC₅₀: 0.33 μM
EGFR-IN-54	EGFR, IC₅₀: 1.623 μM
EGFR-IN-9	EGFR (WT), IC₅₀: 7 nM EGFR^L858R/T790M, IC₅₀: 28 nM				98.84%
EGFR/HER2-IN-16	EGFR, IC₅₀: 6.15 nM HER1, IC₅₀: 9.78 nM
EGFR/HER2/TS-IN-1	EGFR, IC₅₀: 0.203 μM	HER2, IC₅₀: 0.088 μM
HER2-IN-14	EGFR (WT), IC₅₀: 6.3 μM	HER2, IC₅₀: 18 nM
Multi-kinase-IN-6	EGFR, IC₅₀: 0.1 μM
Tyrphostin 8	EGFR, IC₅₀: 560 μM				≥98.0%
EGFR-IN-105		ErbB2, : 0.68 μM
EGFR-IN-45	EGFR, IC₅₀: 0.4 μM
2′-Thioadenosine		ErbB2, IC₅₀: 45 μM
EGFR-IN-40	EGFR, IC₅₀: 5.3 nM
EGFR-IN-53	EGFR, IC₅₀: 8.264 μM
EGFR-IN-51	EGFR, IC₅₀: 0.493 μM EGFR^L858R, IC₅₀: 102.60 μM EGFR^T790M, IC₅₀: 461.63 μM
EGFR-IN-131	EGFR, IC₅₀: 272.9 nM
EGFR-IN-61	EGFR^L858R/T790M, IC₅₀: 42 ± 2 nM EGFR^{L858R/T790M/C797S}, IC₅₀: 137 ± 6 nM EGFR (WT), IC₅₀: 743 ± 20 nM
AG-1478 hydrochloride	EGFR, IC₅₀: 3 nM
EGFR/BRAFV600E-IN-4	EGFR, IC₅₀: 61 nM
EGFR kinase inhibitor 7	EGFR, IC₅₀: 42.3 nM
HER2-targeted peptide H6F		HER2
EGFR/VEGFR2-IN-4	EGFR, IC₅₀: 18.7 nM
EGFR-IN-132	EGFR (WT), IC₅₀: 1.6 nM
EGFR-IN-141	EGFR, IC₅₀: 2.67 nM
EGFR-IN-120	EGFR^{L858R/T790M/C797S}, IC₅₀: 0.053 μM
EGFR-IN-104	EGFR^L858R/T790M, IC₅₀: 0.33 μM EGFR^{L858R/T790M/C797S}, IC₅₀: 0.133 μM
EGFR-IN-140	EGFR, Ki: 0.95 nM EGFR^{L858R/T790M/C797S}, Ki: 2.1 nM
EGFR T790M/L858R-IN-6	EGFR (L858R/T790M)
Nelipepimut-S		HER2
EGFR-IN-136	EGFR (WT), IC₅₀: 20.2 nM EGFR^LR/TM, IC₅₀: 1.2 nM EGFR^19del/TM/CS, IC₅₀: 2.3 nM EGFR^LR/TM/CS, IC₅₀: 2.5 nM
Neptinib	EGFR (WT), IC₅₀: 0.24 nM EGFR^L858R/T790M, IC₅₀: 7.25 nM EGFR^L858R, IC₅₀: 0.46 nM EGFR^T790M, IC₅₀: 1.79 nM
WHI-P180 hydrochloride	EGFR, IC₅₀: 4 μM
Herceptide		HER2
GW837016X		ErbB2
Calotatug ginistinag		HER2
Erlotinib mesylate	EGFR, IC₅₀: 2 nM
SU-4313	EGFR, IC₅₀: 11 μM	HER2, IC₅₀: 16.9 μM			99.31%
D-69491 hydrochloride		HER2

Name
Email *

	Sorry, but the email address you supplied was invalid.

EGFR

EGFR

EGFR Isoform Specific Products:

EGFR Isoform Specific Products:

EGFR Related Products (863)

Recombinant Proteins (77)

Antibodies (19)

EGFR Isoform Comparison

EGFR Related Products (863):